cimetidine

(redirected from Tagamet HB)
Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for cimetidine

a drug (trade name Tagamet) used to treat peptic ulcers by decreasing the secretion of stomach acid

References in periodicals archive ?
In addition to simply assessing the existing antacid market, the team evaluated prior OTC H2 switches, such as Pepcid AC and Tagamet HB, as well as recent non-antacid OTC switches, such as Procter & Gamble's Aleve.
For the Tagamet HB launch last summer, the action plan sent to divisions was designed to motivate as well as inform, and it spanned three pages, not counting order sheets.
marketing the product under the Lamisil AT label; cimetidine suspension, an acid reducer, was transferred to O-T-C status, with SmithKline Beecham Consumer Healthcare making the product under the Tagamet HB 200 name; and Novartis' nicotine replacement transdermal patch (Habitrol) made the switch to nonprescription status.
And, this year, the market was forever changed by the entries of Pepcid AC and Tagamet HB.
The four products that came on the O-T-C market as a result of changes in status in 1995 -- Johnson & Johnson-Merck Consumer Pharmaceutical Co.'s Pepcid AC, Warner-Lambert Co.'s Zantac 75, SmithKline Beecham PLC's Tagamet HB and Whitehall-Robins Healthcare's Axid AR -- account for nearly $550 million a year in antacid sales.
There's the bigger picture to consider as well, says Greg Bradley, director of national accounts, SmithKline Beecham, which launched Tagamet HB. "I think you have to start with the whole impact of Rx-to-OTC conversion on the HBC department in general," Bradley says.
Suppliers indicate the introduction of the four acid controllers - Johnson & Johnson-Merck Consumer Pharmaceuticals' Pepcid AC, Warner-Lambert Co.'s Zantac 75, SmithKline Beecham PLC's Tagamet HB and Whitehall-Robins' Axid AR - were just the boost the antacids category needed after a period of minimal growth in the early 1990s.
Rather, the quartet - Zantac 75; Pepcid AC from Johnson & Johnson-Merck Consumer Pharmaceuticals Co.; Tagamet HB from SmithKline Beecham PLC; and Axid AR from Whitehall-Robins Healthcare - are low-strength versions of prescription drugs that are used to treat ulcers and various other problems in the digestive tract.
The new O-T-C medications - Pepcid AC, from Johnson & Johnson-Merck Consumer Pharmaceuticals Co.; Tagamet HB, from SmithKline Beecham PLC; Axid AR, from Whitehall-Robins Healthcare; and Zantac 75, from Warner-Lambert Co.
Rather, the quartet - Pepcid AC, from Johnson & Johnson-Merck Consumer Pharmaceuticals Co.; Tagamet HB, from SmithKline Beecham PLC; Axid AR, from Whitehall-Robins Healthcare; and Zantac 75, from Warner-Lambert - are low-strength versions of prescription medications that previously were used to treat ulcers and other digestive disorders.
Quinn is among the many marketers and retailers who say the acid controllers - Zantac 75, Johnson & Johnson-Merck Consumer Pharmaceuticals Co.'s Pepcid AC, SmithKline Beecham PLC's Tagamet HB and Whitehall-Robins' Axid AR - were just the boost drug chains needed to revive what had become a stagnant antacids market.
Other major pharmaceutical companies touting O-T-C versions of H2 blockers were Johnson & Johnson Merck Consumer Pharmaceuticals Co., which makes Pepcid AC, and SmithKline Beecham, which produces Tagamet HB.
The new products, which actually prevent the formation of stomach acid rather than relieve it after the fact like traditional antacids, include the three already-approved items - Pepcid AC from Johnson & Johnson/Merck Consumer Pharmaceuticals Co., SmithKline Beecham PLC's Tagamet HB and Zantac 75 from Glaxo Wellcome - as well as American Home Products Corp.'s Axid, which is expected to win approval shortly.
The Wall Street Journal reported that the O-T-C heartburn remedy market has expanded 38% over last year due to the debut of J&J-Merck's Pepcid AC and SmithKline Beecham's Tagamet HB.
The four that are leading the way are Johnson & Johnson/Merck Consumer Pharmaceuticals Co.'s Pepcid AC; SmithKline Beecham PLC's Tagamet HB; Glaxo Wellcome's Zantac 75; and American Home Products Corp.'s (AHP's) Axid.